Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. filed a current report to share that it issued a press release on January 12, 2026. The release reaffirms the company’s achievements in 2025 and announces key anticipated milestones for 2026, highlighting its recent progress and future business, regulatory, or financial targets. The press release is furnished as Exhibit 99.1 and incorporated by reference, and the company includes customary cautionary language that statements about expected future milestones are forward-looking and subject to various risks and uncertainties.
Microbot Medical Inc. reported that Emory University Hospital in Atlanta has become the first hospital in the world to adopt its LIBERTY® Endovascular Robotic System for patient care. This marks the system’s transition from development and evaluation into real-world clinical use at a major academic medical center.
The company is also collaborating with Emory to establish an Endovascular Robotics Program within interventional radiology. This collaboration is intended to integrate robotic technology into clinical workflows and may help build clinical experience and visibility for the LIBERTY system over time.
Microbot Medical Inc. is registering up to 14,688,572 shares of common stock for resale by existing selling stockholders, issuable upon exercise of outstanding preferred investment options. The company itself is not selling shares in this offering and will not receive proceeds from any resale, although it may receive up to approximately $64.8 million in gross proceeds if all 14,688,572 options are exercised for cash, which would be used for working capital. Shares outstanding were 67,158,044 as of November 14, 2025. Microbot highlights recent progress for its LIBERTY® Endovascular Robotic Surgical System, including U.S. FDA 510(k) clearance in September 2025 and ISO 13485:2016 certification, and notes plans to pursue CE Mark approval in the second half of 2026. The company also discusses new patents in Japan, China and the U.S., and outlines risks related to ongoing regional military conflicts affecting its Israel-based operations.
Microbot Medical Inc. is registering up to 900,153 shares of common stock for resale by certain selling stockholders, consisting of shares issuable upon exercise of outstanding preferred investment options. The company is not selling any shares in this offering and will not receive proceeds from stockholder resales, though it may receive up to approximately $2.1 million in gross proceeds if all 900,153 options are exercised for cash.
Microbot is a medical device company developing next-generation robotic systems for minimally invasive endovascular procedures, led by its LIBERTY® Endovascular Robotic Surgical System. On September 8, 2025, LIBERTY received FDA 510(k) clearance for peripheral endovascular procedures, and a limited U.S. market release began on November 5, 2025, with a broader launch anticipated in April 2026. The company reports recent patents in Japan, the United States, and China, ISO 13485:2016 certification supporting a CE Mark it anticipates in the second half of 2026, and collaboration with Emory University on autonomous robotics. It also discusses risks from ongoing military conflict affecting its Israel-based operations, noting no material adverse effects as of the prospectus date but no specific contingency plans.
Microbot Medical (MBOT) reported Q3 2025 results, highlighting a larger cash position to support commercialization preparation and ongoing R&D. Cash and cash equivalents were $6.7 million with marketable securities of $73.5 million, bringing total current assets to $80.8 million as of September 30, 2025. The company recorded a net loss of $3.6 million (basic and diluted loss per share of $0.07) for the quarter.
Shareholders’ equity rose to $78.2 million, aided by equity financings and warrant exercises during the year. Shares outstanding were 65,833,556 as of September 30, 2025; the company later reported 67,158,044 shares as of November 12, 2025. Management noted funds are sufficient to operate for more than twelve months from the financial statement issuance date.
Operationally, the FDA granted 510(k) clearance for the LIBERTY Endovascular Robotic Surgical System, and the company increased authorized common shares to 120,000,000 in June 2025 to support capital needs. Marketable securities expanded as proceeds were invested in money market mutual funds.
Microbot Medical (MBOT) announced U.S. commercial availability of its LIBERTY Endovascular Robotic System on a limited basis. The company is initiating a limited market release to selected high procedure volume regions where it has already experienced preliminary demand.
The update was shared via a press release furnished under Regulation FD and listed as Exhibit 99.1. This marks an initial commercialization step intended to introduce LIBERTY to targeted centers in the United States.
Microbot Medical Inc. filed Amendment No. 1 to its Form S-3 registration statement. The amendment adds Rule 473(b) language for automatic effectiveness 20 days following filing and updates a cross-reference in the exhibit index. It does not modify any provision of the prospectus, and a preliminary prospectus has been omitted.
The filing states effectiveness will occur in accordance with Section 8(a) of the Securities Act. Listed issuance and distribution expenses total $25,000.00, including an SEC registration fee of $404.02, with legal, accounting, and miscellaneous costs itemized.
Microbot Medical Inc. (MBOT) filed Amendment No. 1 to its shelf registration statement, stating it is being made solely to add Rule 473(b) language for automatic effectiveness 20 days after filing and to update a cross-reference in the Exhibit Index. The amendment does not modify any prospectus, and a preliminary prospectus has been omitted.
The filing notes the registration will become effective in accordance with Section 8(a), and the company may amend to delay or change effectiveness if the SEC resumes full operation beforehand. Disclosed offering-related expenses total $27,000.00, including an SEC registration fee of $6,592.60, legal fees of $5,000.00, accounting fees of $12,000.00, and miscellaneous expenses of $3,407.40.
Microbot Medical (MBOT) reported it will exhibit its LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami, FL on October 17–19, 2025. This marks the first medical meeting where the company will commercially exhibit the LIBERTY® System following its FDA 510(k) clearance.
The company also announced it has recently completed the hiring and on‑boarding of its commercial leadership team. The disclosure was furnished under Regulation FD.
Microbot Medical announced a partnership with a U.S.-based third-party logistics provider to support commercialization of its FDA-cleared LIBERTY Endovascular Robotic System. The company plans a limited market release in the fourth quarter of 2025, followed by a broader launch in April 2026 aligned with the Society of Interventional Radiology conference.
The disclosure was furnished under Regulation FD and as an Other Event, with a related press release included as Exhibit 99.1.